Burkitt Lymphoma  Pipeline Review, H2 2012

Burkitt Lymphoma Pipeline Review, H2 2012

Oct 2012 Global Markets Direct Lymphoma116 Pages Price :
$ 2000

Burkitt Lymphoma Pipeline Review, H2 2012

Global Markets Directs, 'Burkitt Lymphoma Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Burkitt Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Burkitt Lymphoma. Burkitt Lymphoma Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Burkitt Lymphoma.
  • A review of the Burkitt Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Burkitt Lymphoma pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Burkitt Lymphoma.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Burkitt Lymphoma pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Burkitt Lymphoma Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Burkitt Lymphoma 10
Burkitt Lymphoma Therapeutics under Development by Companies 12
Burkitt Lymphoma Therapeutics under Investigation by Universities/Institutes 13
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Burkitt Lymphoma Therapeutics Products under Development by Companies 17
Burkitt Lymphoma Therapeutics Products under Investigation by Universities/Institutes 18
Companies Involved in Burkitt Lymphoma Therapeutics Development 21
Celldex Therapeutics, Inc. 21
Burkitt Lymphoma Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Combination Products 23
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 29
CDX-1127 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
LBH589 + RAD001 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
ixabepilone - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Therapeutic allogeneic lymphocytes program - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Campath + Fludarabine + Cyclosporine + Mycophenolate Mofetil + Peripheral Stem Cell Transplantation - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 36
Filgrastim + Rituximab + Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin Hydrochloride + Etoposide + Ifosfamide + Leucovorin + Methotrexate + Prednisone + Vincristine - Drug Profile 37
Product Description 37
Mechanism of Action 39
R&D Progress 40
RAD001 + Revlimid - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Rituximab + Methotrexate + Cytarabine + G-CSF + Radiation Therapy - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
R-CODOX-M + Leucovorin + Filgrastim + Cytarabine - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 45
R-CODOX-M + Leucovorin + Filgrastim + IVAC - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 48
Filgrastim + Rituximab + Cyclophosphamide + Cytarabine + Leucovorin Calcium + Methotrexate + Prednisone + Therapeutic hydrocortisone + Vincristine - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 51
Cyclophosphamide + Vincristine + Prednisone + Doxorubicin - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 54
Cyclophosphamide + Vincristine + Prednisone + Methotrexate - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 56
Cyclophosphamide + Vincristine + Prednisone + Cytarabine - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 58
Rituximab + Carboplatin + Etoposide + Ifosfamide + Vorinostat - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 60
rituximab - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Rituximab + Hyper-CVAD + Pegfilgrastim + Cytarabine + Methotrexate - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 63
Treanda + Carboplatin + Rituximab + Etoposide - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 66
Rituximab + Etoposide + Cyclophosphamide + Doxorubicin + Vincristine + Prednisone + Filgrastim - Drug Profile 67
Product Description 67
Mechanism of Action 68
R&D Progress 68
Treg Cells + CD3-Teff Cells + Fludarabine + Cyclophosphamide + Radiation Therapy + Umbilical Cord Blood Transplantation - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 71
Busulfan + Cyclophosphamide + Allogeneic Bone Marrow Transplantation + Methylprednisolone + Methotrexate + Cyclosporine - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 73
Lenalidomide + Rituximab + Carmustine + Etoposide + Cytarabine + Melphalan + Autologous Hematopoietic Stem Cell Transplant - Drug Profile 74
Product Description 74
Mechanism of Action 75
R&D Progress 75
Filgrastim + Cyclophosphamide + Cytarabine + Doxorubicin Hydrochloride + Etoposide + Ifosfamide + Leucovorin Calcium + Methotrexate + Vincristine Sulfate - Drug Profile 77
Product Description 77
Mechanism of Action 78
R&D Progress 79
Filgrastim + Cyclophosphamide + Cytarabine + Doxorubicin Hydrochloride + Etoposide + Ifosfamide + Leucovorin Calcium + Methotrexate + Vincristine Sulfate - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 81
Filgrastim + Pegfilgrastim + Rituximab + Cyclophosphamide + Cytarabine + Doxorubicin Hydrochloride + Etoposide + Ifosfamide + Leucovorin Calcium + Liposomal Cytarabine + Methotrexate + Therapeutic Hydrocortisone + Vincristine Sulfate - Drug Profile 83
Product Description 83
Mechanism of Action 84
R&D Progress 85
Carmustine + Etoposide + Cytarabine + Fludarabine Phosphate + Cyclophosphamide + Tacrolimus + Mycophenolate Mofetil + Melphalan + Filgrastim + Stem Cell Transplantation + Radiation Therapy - Drug Profile 87
Product Description 87
Mechanism of Action 88
R&D Progress 89
Carmustine + Etoposide + Cytarabine + Fludarabine Phosphate + Cyclophosphamide + Cyclosporine + Mycophenolate Mofetil + Melphalan + Therapeutic Autologous Lymphocytes + Stem Cell Transplantation + Radiation Therapy - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 91
Fludarabine Phosphate + Total-Body Irradiation + Peripheral Blood Stem Cell Transplantation + Cyclosporine + Mycophenolate Mofetil - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 94
Prednisone + Vincristine + Cytarabine + Methotrexate + Etoposide + Cyclophosphamide + Doxorubicin - Drug Profile 95
Product Description 95
Mechanism of Action 96
R&D Progress 96
Busulfan + Cyclophosphamide + Anti-Thymocyte Globulin + Methylprednisolone + Cyclosporine + Mycophenolate Mofetil + Allogeneic Hematopoietic Stem Cell Transplantation + Umbilical Cord Blood Transplantation - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 99
G-CSF + Rituximab + Cyclophosphamide + Cytarabine + Leucovorin Calcium + Methotrexate + Prednisone + Therapeutic Hydrocortisone + Vincristine - Drug Profile 100
Product Description 100
Mechanism of Action 101
R&D Progress 102
Rituximab + Revlimid - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
Rituximab + Cyclophosphamide + Prednisone + Dexamethasone + Vincristine + Methotrexate + Ifosphamide + Teniposide + Etoposide + Cytarabine + Adriamycin + Vindesine - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 107
panobinostat - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
131I-BC8 (Anti-CD45) Antibody + Autologous Hematopoietic Stem Cell Transplantation - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
Burkitt Lymphoma Therapeutics Drug Profile Updates 112
Burkitt Lymphoma Therapeutics Discontinued Products 113
Burkitt Lymphoma Therapeutics - Dormant Products 114

Appendix 115
Methodology 115
Coverage 115
Secondary Research 115
Primary Research 115
Expert Panel Validation 115
Contact Us 116
Disclaimer 116

List of Table


Number of Products Under Development for Burkitt Lymphoma, H2 2012 10
Products under Development for Burkitt Lymphoma Comparative Analysis, H2 2012 11
Number of Products under Development by Companies, H2 2012 12
Number of Products under Investigation by Universities/Institutes, H2 2012 14
Comparative Analysis by Mid Clinical Stage Development, H2 2012 15
Comparative Analysis by Early Clinical Stage Development, H2 2012 16
Products under Development by Companies, H2 2012 17
Products under Investigation by Universities/Institutes, H2 2012 18
Celldex Therapeutics, Inc., H2 2012 21
Assessment by Monotherapy Products, H2 2012 22
Assessment by Combination Products, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 28
Burkitt Lymphoma Therapeutics Drug Profile Updates 112
Burkitt Lymphoma Therapeutics Discontinued Products 113
Burkitt Lymphoma Therapeutics Dormant Products 114

List of Chart


Number of Products under Development for Burkitt Lymphoma, H2 2012 10
Products under Development for Burkitt Lymphoma Comparative Analysis, H2 2012 11
Products under Development by Companies, H2 2012 12
Products under Investigation by Universities/Institutes, H2 2012 13
Mid Clinical Stage Products, H2 2012 15
Early Clinical Stage Products, H2 2012 16
Assessment by Monotherapy Products, H2 2012 22
Assessment by Combination Products, H2 2012 23
Assessment by Route of Administration, H2 2012 24
Assessment by Stage and Route of Administration, H2 2012 25
Assessment by Molecule Type, H2 2012 26
Assessment by Stage and Molecule Type, H2 2012 27

Ask for discount before buying this report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Country :
  • Your Requirement
  • Security Code *
* denotes fields which must be completed

Buy This Report


Select License Type :

$ 2000
$ 4000

Do you wish to check sample of this report?

Have Query?


Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email : sales@marketresearchhub.com

Back To Top